New Zealand markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
98.35+1.07 (+1.10%)
At close: 04:00PM EDT
97.01 -1.34 (-1.36%)
After hours: 07:50PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close97.28
Open98.50
Bid0.00 x 1000
Ask0.00 x 1100
Day's range97.40 - 98.55
52-week range92.19 - 108.78
Volume2,221,706
Avg. volume1,604,108
Market cap200.674B
Beta (5Y monthly)0.47
PE ratio (TTM)22.35
EPS (TTM)4.40
Earnings dateN/A
Forward dividend & yield3.78 (3.84%)
Ex-dividend date07 Mar 2024
1y target est113.07
  • Insider Monkey

    Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript

    Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript April 23, 2024 Novartis AG isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and good afternoon, and welcome to the Novartis Q1 2024 Results Release Conference Call and Live Webcast. […]

  • Zacks

    Company News for Apr 24, 2024

    Companies in The News Are: UPS,PM,NVS,IVZ

  • GlobeNewswire

    Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

    There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, dem